Biotricity reports FY22 revenue $7.7M (+126% YoY); Q4 revenue $2.15M (+81%); net loss $30.2M

BIOTRICITY INC.

2024-Q1 EPS reported -$0.10 revenue$2,056,052

FY22 revenue $7.7M (+126% YoY); gross margin improved to 60% from 38% in FY21.
Q4 FY22 revenue $2.15M (+81% YoY); gross margin 67% vs 60% in Q4 FY21.
FY22 net loss $30.2M ($0.665 per share); adjusted loss per share $0.48.
Cash $12M at March 31, 2022; closed $12M non-convertible debt and extinguished $1.6M legacy debt.
Expanded network to 300+ centers, 1,500 cardiologists; launched Biotres, Bioheart, Biokit after FDA clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.